Cutting-Edge Advances in HIV Prevention and Treatment: Breakthroughs and Innovations 2023

UNAIDS aims to end the HIV and AIDS epidemic by 2030 with support from 11 UN cosponsors.

Challenges in HIV Management

HIV is a retrovirus that integrates its genetic material into human DNA, complicating treatment and leaving no cure currently available. Untreated HIV can lead to acquired immunodeficiency syndrome (AIDS).

What is AIDS?

AIDS occurs when HIV damages the immune system. Many people with HIV manage their condition effectively and do not develop AIDS if they receive treatment.

A person is diagnosed with AIDS when their CD4 cell count drops below 200 cells per cubic millimeter, or when they get opportunistic infections. Typically, without treatment, individuals with AIDS live about three years.

While treatment helps manage HIV, some immune cells become dormant but retain viral DNA. They can reactivate if treatment stops.

Dr. Emmanuel Ho explains, “HIV can hide in dormancy within our cells for long periods. Once active, it can quickly replicate.” He adds, “HIV can evade the immune system and resist treatments, harming the immune cells we need to fight it.”

Currently, combined antiretroviral therapy (cART) is the primary treatment for HIV. cART combines antiviral drugs to stop HIV reproduction.

Dr. Jamie Mann notes, “cART reduces virus levels to undetectable levels, helping to protect the immune system.” However, some dormant viruses remain unaffected by cART, requiring ongoing treatment. Long-term use of cART can lead to toxicity and drug resistance.

Global Disparities in Treatment Access

• About 10 million people with HIV lack antiretroviral therapy. In 2023, only 43% of children living with HIV access life-saving medication.
• More than 25 million people with HIV in 2022 were in Africa. Women in sub-Saharan Africa made up 63% of new infections, while globally, this number was 46%.
• Adolescent girls and young women in sub-Saharan Africa face higher risks due to violence, stigma, and poverty.
• Globally, HIV prevalence is 14 times higher in transgender individuals, 11 times higher in men who have sex with men, 7 times higher among people who inject drugs, and 4 times higher among sex workers compared to the general adult population.

Dr. Mann asserts that stigma, discrimination, and access to healthcare affect different groups facing unique challenges in treating HIV.

Protecting Against HIV Transmission

Dr. Emmanuel Ho’s research group works on innovative drug delivery strategies to combat HIV/AIDS. Recently, he developed a novel nanomedicine using small interfering RNAs (siRNAs) to fight the virus.

siRNAs are molecules that can silence specific genes. Ho explains, “We can create siRNAs to target genes that enhance HIV infection.”

The nanomedicine aims to lower the expression of CCR5, a protein that helps HIV enter cells. “By reducing CCR5, we hope to limit HIV infection,” says Ho.

Looking Ahead: Is a Cure Possible?

While HIV is treatable, there is no cure. Dr. Jamie Mann is exploring new vaccines to address this gap.

In a study, Mann’s team found that their treatment could eliminate HIV from immune cells containing latent reservoirs. This method showed promise against various HIV strains, indicating potential for global application.

The research team plans clinical trials to assess treatment effectiveness in a controlled environment, inching closer to a possible cure.

Advancements in research offer hope for new HIV treatments, but achieving a global solution needs improved access to prevention, treatment, and education for at-risk communities.